These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 34958982)

  • 41. Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma.
    Covar RA; Szefler SJ; Martin RJ; Sundstrom DA; Silkoff PE; Murphy J; Young DA; Spahn JD
    J Pediatr; 2003 May; 142(5):469-75. PubMed ID: 12756375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biological treatments for severe asthma.
    Assaf SM; Hanania NA
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):379-386. PubMed ID: 31169594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting.
    Cameli P; Bergantini L; d'Alessandro M; Perruzza M; Cekorja B; Perillo F; Massa E; Ruzza A; Fossi A; Beltrami V; Sestini P; Bargagli E
    Int Arch Allergy Immunol; 2020; 181(8):606-612. PubMed ID: 32516771
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of nasal polyps on endotype and phenotype in patients with moderate to severe asthma.
    Chan R; Lipworth B
    Ann Allergy Asthma Immunol; 2021 Nov; 127(5):548-552. PubMed ID: 34153444
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exhaled nitric oxide: a test for diagnosis and control of asthma?
    Katial R; Stewart L
    Curr Allergy Asthma Rep; 2007 Nov; 7(6):459-63. PubMed ID: 17986377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.
    Casale TB; Chipps BE; Rosén K; Trzaskoma B; Haselkorn T; Omachi TA; Greenberg S; Hanania NA
    Allergy; 2018 Feb; 73(2):490-497. PubMed ID: 28859263
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exhaled nitric oxide--is it really a good marker of airway inflammation in bronchial asthma?
    Tsujino I; Nishimura M; Kamachi A; Makita H; Munakata M; Miyamoto K; Kawakami Y
    Respiration; 2000; 67(6):645-51. PubMed ID: 11124647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relationship between total serum immunoglobulin E levels, fractional exhaled breath nitric oxide levels and absolute blood eosinophil counts in atopic and non-atopic asthma: a controlled comparative study.
    Shrestha SK; Drews A; Sharma L; Pant S; Shrestha S; Neopane A
    J Breath Res; 2018 Feb; 12(2):026009. PubMed ID: 29068321
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhaled corticosteroid dose response in asthma: Should we measure inflammation?
    Anderson WJ; Short PM; Jabbal S; Lipworth BJ
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):179-185. PubMed ID: 28065396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma.
    Caruso M; Crisafulli E; Demma S; Holgate S; Polosa R
    Expert Opin Biol Ther; 2013 Mar; 13(3):393-402. PubMed ID: 23289846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Primary care of asthma: new options for severe eosinophilic asthma.
    Skolnik NS; Carnahan SP
    Curr Med Res Opin; 2019 Jul; 35(7):1309-1318. PubMed ID: 30880484
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of nasal steroid treatment on airway inflammation determined by exhaled nitric oxide in allergic schoolchildren with perennial rhinitis and asthma.
    Pedroletti C; Lundahl J; Alving K; Hedlin G
    Pediatr Allergy Immunol; 2008 May; 19(3):219-26. PubMed ID: 18399898
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers.
    Santus P; Saad M; Damiani G; Patella V; Radovanovic D
    Pharmacol Res; 2019 Aug; 146():104296. PubMed ID: 31173886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide.
    Couillard S; Laugerud A; Jabeen M; Ramakrishnan S; Melhorn J; Hinks T; Pavord I
    Thorax; 2022 Feb; 77(2):199-202. PubMed ID: 34362839
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biomarkers for severe eosinophilic asthma.
    Yancey SW; Keene ON; Albers FC; Ortega H; Bates S; Bleecker ER; Pavord I
    J Allergy Clin Immunol; 2017 Dec; 140(6):1509-1518. PubMed ID: 29221581
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma.
    van Rensen EL; Straathof KC; Veselic-Charvat MA; Zwinderman AH; Bel EH; Sterk PJ
    Thorax; 1999 May; 54(5):403-8. PubMed ID: 10212103
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prevalence and disease burden of severe eosinophilic asthma in Japan.
    Nagasaki T; Sato K; Kume N; Oguma T; Sunadome H; Ito I; Izuhara Y; Okamoto K; Kobayashi S; Ohno T; Mizukami A; Kobayashi A; Kaise T; Kuroda T; Mishima M; Matsumoto H
    J Asthma; 2019 Nov; 56(11):1147-1158. PubMed ID: 30822174
    [No Abstract]   [Full Text] [Related]  

  • 60. Definition, Phenotyping of Severe Asthma, Including Cluster Analysis.
    Casanova S; Ahmed E; Bourdin A
    Adv Exp Med Biol; 2023; 1426():239-252. PubMed ID: 37464124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.